Valneva: Successful Outcome of its Annual General Meeting
Valneva announced that shareholders approved all resolutions at the Annual General Meeting. In addition, Dr. Gerd Zettlmeissl was appointed Chair of the Board of Directors.
Valneva SE today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company’s Annual General Meeting (AGM), held in Lyon, France. Key resolutions adopted included the approval of the 2025 financial statements, renewal of authorizations granted to the Board of Directors regarding the Company’s share capital, and the transfer of Valneva’s registered office to Lyon following the closure of its Nantes site. :contentReference[oaicite:0]{index=0}
Shareholders also approved the reappointment of five Board members. Anne-Marie Graffin, James Sulat and Kathrin Jansen were reappointed for one-year terms, James Connelly for a two-year term, and Valneva’s Chief Executive Officer Thomas Lingelbach for a three-year term. :contentReference[oaicite:1]{index=1}
At a Board meeting held following the AGM, Dr. Gerd Zettlmeissl, an independent director, was appointed as Chair of the Board of Directors. Dr. Zettlmeissl is a vaccine expert and biotech entrepreneur with more than 40 years of scientific and leadership experience in the biopharmaceutical industry. He succeeds Anne-Marie Graffin, who chaired the Board for the past three years and who will continue as Vice-chair of the Board. :contentReference[oaicite:2]{index=2}
Detailed voting results will be made available in the “Investors & Media” section of Valneva’s corporate website in the coming days. :contentReference[oaicite:3]{index=3}
Kontakt
Valneva Media and Investor Relations
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
Telefon: +33 (0)6 4516 7099
E-Mail: laetitia.bachelot-fontaine@valneva.com
Joshua Drumm, Ph.D.
VP Global Investor Relations
Telefon: +1 917 815 4520
E-Mail: joshua.drumm@valneva.com